CD54/ICAM-1 Antibody (Rabbit mAb) [L16P13]

Application: Reactivity: Mouse

Usage Information

Dilution
WB1:1000 IHC1:2000

Application
WB, IHC

Reactivity
Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
58 kDa 80-110 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
CD54/ICAM-1 Antibody (Rabbit mAb) [L16P13] detects endogenous levels of total CD54/ICAM-1 protein.

Clone
L16P13

Synonym(s)
CD54, Intercellular adhesion molecule 1, ICAM-1, MALA-2, MyD10, Icam1

Background
ICAM1, or intercellular adhesion molecule 1, is an immunoglobulin superfamily cell-adhesion receptor expressed at low basal levels on endothelial cells and various leukocytes and strongly inducible by proinflammatory cytokines, where it serves as a central organizer of leukocyte trafficking and immune synapse formation. The ectodomain is composed of multiple Ig-like domains that present binding surfaces for β2 integrins, including ITGAL:ITGB2 (LFA‑1) and ITGAM:ITGB2 (Mac‑1), as well as other ligands such as fibrinogen and hyaluronan, while the short cytoplasmic tail connects to the actin cytoskeleton and signaling adaptors to support outside‑in signaling during adhesion. Engagement of ICAM1 by LFA‑1 on T cells stabilizes T cell–endothelial and T cell–antigen-presenting cell contacts and contributes to formation of the immunological synapse, providing a calibrated adhesion system that allows T‑cell receptor signaling strength to be translated into stable conjugate formation, costimulation and efficient cytotoxic or helper responses. Binding of Mac‑1 on activated neutrophils to ICAM1 on stimulated endothelium under shear stress supports firm adhesion and crawling, positioning neutrophils for trans-endothelial migration at inflamed sites. During leukocyte trans-endothelial migration, ICAM1 ligation triggers assembly of endothelial “apical cups” enriched in F‑actin and caveolae by recruiting ARHGEF26/SGEF and activating the small GTPase RHOG, which reshapes the endothelial surface around adherent leukocytes and facilitates diapedesis. ICAM1 engagement also activates endothelial nitric oxide synthase through Ca²⁺ and AMP‑activated protein kinase, linking adhesion to vasoregulatory and barrier-signaling programs that further influence leukocyte passage. At the signaling level, ICAM1 crosslinking induces tyrosine phosphorylation cascades, kinase activation and transcription factor engagement, leading to changes in cytokine production, membrane protein expression, reactive oxygen species generation and, in some contexts, proliferation, making it more than a passive adhesion anchor. Transcriptional regulation of ICAM1 expression is driven by promoter elements including a κB site responsive to TNF, IL‑1, LPS and phorbol esters, and expression is inhibited by glucocorticoids, placing ICAM1 within NF‑κB–dependent inflammatory gene programs that can be pharmacologically modulated. ICAM1 is robustly expressed on epithelial and tumor cells, where it participates in cell–cell aggregation, for example through interaction with the mucin MUC1, and contributes to antigen presentation and cytotoxic T‑cell activation via costimulatory interactions with T‑cell integrins. Shed soluble ICAM1 is detectable in plasma and is elevated in many pathological states including malignancies, autoimmune and allergic diseases, atherosclerosis, ischemia, and transplant rejection, making ICAM1 a useful biomarker for inflammatory and immune dysregulation.

Background

ICAM1, or intercellular adhesion molecule 1, is an immunoglobulin superfamily cell-adhesion receptor expressed at low basal levels on endothelial cells and various leukocytes and strongly inducible by proinflammatory cytokines, where it serves as a central organizer of leukocyte trafficking and immune synapse formation. The ectodomain is composed of multiple Ig-like domains that present binding surfaces for β2 integrins, including ITGAL:ITGB2 (LFA‑1) and ITGAM:ITGB2 (Mac‑1), as well as other ligands such as fibrinogen and hyaluronan, while the short cytoplasmic tail connects to the actin cytoskeleton and signaling adaptors to support outside‑in signaling during adhesion. Engagement of ICAM1 by LFA‑1 on T cells stabilizes T cell–endothelial and T cell–antigen-presenting cell contacts and contributes to formation of the immunological synapse, providing a calibrated adhesion system that allows T‑cell receptor signaling strength to be translated into stable conjugate formation, costimulation and efficient cytotoxic or helper responses. Binding of Mac‑1 on activated neutrophils to ICAM1 on stimulated endothelium under shear stress supports firm adhesion and crawling, positioning neutrophils for trans-endothelial migration at inflamed sites. During leukocyte trans-endothelial migration, ICAM1 ligation triggers assembly of endothelial “apical cups” enriched in F‑actin and caveolae by recruiting ARHGEF26/SGEF and activating the small GTPase RHOG, which reshapes the endothelial surface around adherent leukocytes and facilitates diapedesis. ICAM1 engagement also activates endothelial nitric oxide synthase through Ca²⁺ and AMP‑activated protein kinase, linking adhesion to vasoregulatory and barrier-signaling programs that further influence leukocyte passage. At the signaling level, ICAM1 crosslinking induces tyrosine phosphorylation cascades, kinase activation and transcription factor engagement, leading to changes in cytokine production, membrane protein expression, reactive oxygen species generation and, in some contexts, proliferation, making it more than a passive adhesion anchor. Transcriptional regulation of ICAM1 expression is driven by promoter elements including a κB site responsive to TNF, IL‑1, LPS and phorbol esters, and expression is inhibited by glucocorticoids, placing ICAM1 within NF‑κB–dependent inflammatory gene programs that can be pharmacologically modulated. ICAM1 is robustly expressed on epithelial and tumor cells, where it participates in cell–cell aggregation, for example through interaction with the mucin MUC1, and contributes to antigen presentation and cytotoxic T‑cell activation via costimulatory interactions with T‑cell integrins. Shed soluble ICAM1 is detectable in plasma and is elevated in many pathological states including malignancies, autoimmune and allergic diseases, atherosclerosis, ischemia, and transplant rejection, making ICAM1 a useful biomarker for inflammatory and immune dysregulation.

References
https://pubmed.ncbi.nlm.nih.gov/8834767/ https://pubmed.ncbi.nlm.nih.gov/10924857/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%